



One Step Cocaine Test Strip (Urine) Package Insert

REF 1185-S

A rapid, one step test for the qualitative detection of Cocaine metabolites in human urine.
For professional, *in vitro* diagnostic use only.

INTENDED USE

The COC One Step Cocaine Test Strip (Urine) is a rapid chromatographic immunoassay for the qualitative detection of Cocaine metabolite, Benzoylgonine, in human urine at a cut-off concentration of 300 ng/mL. This test will detect other related compounds, please refer to the Analytical Specificity table in this package insert.

This assay provides only a qualitative, preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

SUMMARY

Cocaine, is a potent central nervous system (CNS) stimulant and a local anesthetic. Initially, it brings about extreme energy and restlessness while gradually resulting in tremors, over-sensitivity and spasms. In large amounts, Cocaine causes fever, unresponsiveness, and difficulty in breathing and unconsciousness.

Cocaine is often self-administered by nasal inhalation, intravenous injection and free-base smoking. It is excreted in the urine in a short time primarily as Benzoylgonine.^{1,2} Benzoylgonine, a major metabolite of Cocaine, has a longer biological half-life (5 - 8 hours) than Cocaine (0.5 - 1.5 hours), and can generally be detected for 24-48 hours after Cocaine exposure.²

The COC One Step Cocaine Test Strip (Urine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Cocaine metabolite in urine. The COC One Step Cocaine Test Strip (Urine) yields a positive result when the Cocaine metabolite in urine exceeds 300 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

PRINCIPLE

The COC One Step Cocaine Test Strip (Urine) is an immunoassay based on the principle of competitive binding. Drugs which may be present in the urine specimen compete against the drug conjugate for binding sites on the antibody.

During testing, a urine specimen migrates upward by capillary action. Benzoylgonine, if present in the urine specimen below 300 ng/mL, will not saturate the binding sites of antibody in the test strip. The antibody coated particles will then be captured by immobilized Benzoylgonine conjugate and a visible colored line will appear in the test line region. The colored line will not form in the test line region if the Benzoylgonine level is above 300 ng/mL because it will saturate all the binding sites of antibodies.

A drug-positive urine specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative urine specimen or a specimen containing a drug concentration less than the cut-off will generate a line in the test line region. To serve as a procedural control, a colored line will always appear at the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.

REAGENTS

The test strip contains mouse monoclonal anti-Benzoylgonine antibody-coupled particles and Benzoylgonine-protein conjugate. A goat antibody is employed in the control line system.

PRECAUTIONS

- For professional *in vitro* diagnostic use only. Do not use after the expiration date.
- The test strip should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used test strip should be discarded according to local regulations.

STORAGE AND STABILITY

Store as packaged in the sealed pouch either at room temperature or refrigerated (2-30°C). The test strip is stable through the expiration date printed on the sealed pouch. The test strip must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

SPECIMEN COLLECTION AND PREPARATION

Urine Assay

The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear supernatant for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed before testing.

MATERIALS


Materials Provided

- Test strips
 - Package insert
- Specimen collection container
 - Timer

DIRECTIONS FOR USE

Allow the test strip, urine specimen, and/or controls to equilibrate to room temperature (15-30°C) prior to testing.

- Bring the pouch to room temperature before opening it. Remove the test strip from the sealed pouch and use it as soon as possible.
- With arrows pointing toward the urine specimen, immerse the test strip vertically in the urine specimen for at least 10-15 seconds. Do not pass the maximum line (MAX) on the test strip when immersing it. See the illustration below.
- Place the test strip on a non-absorbent flat surface, start the timer and wait for the colored line(s) to appear. Read results at 5 minutes. Do not interpret the result after 10 minutes.



INTERPRETATION OF RESULTS

(Please refer to the illustration above)

NEGATIVE: * Two lines appear. One colored line should be in the control line region (C), and another apparent colored line should be in the test line region (T). This negative result indicates that the Benzoylgonine concentration is below the detectable level (300 ng/mL).

*NOTE: The shade of color in the test line region (T) may vary, but it should be considered negative whenever there is even a faint colored line.

POSITIVE: One colored line appears in the control line region (C). No line appears in the test line region. This positive result indicates that the Benzoylgonine concentration is above the detectable level (300 ng/mL).

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test strip. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL

A procedural control is included in the test. A colored line appearing in the control line region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATION

- The COC One Step Cocaine Test Strip (Urine) provides only a qualitative, preliminary analytical result. A secondary quantitative analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method.^{3,4}
- It is possible that technical or procedural errors, as well as other interfering substances in the urine specimen may cause erroneous results.
- Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- A positive result does not indicate level of intoxication, administration route or concentration in urine.
- A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- Test does not distinguish between drugs of abuse and certain medications.

PERFORMANCE CHARACTERISTICS

Accuracy

A side-by-side comparison was conducted by laboratory personnel using the COC One Step Cocaine Test Strip (Urine) and a commercially available rapid test. Testing was performed on 300 clinical specimens previously collected from subjects present for Drug Screen Testing. Ten percent of the specimens employed were either at -25% or +25% level of the cut-off concentration of 300 ng/mL Benzoylgonine. Presumptive positive results were confirmed by GC/MS. The following results were tabulated:

Method	Other COC Rapid Test		Total Results
	Positive	Negative	
COC One Step Test Strip	Positive	0	136
	Negative	157	164
Total Results	143	157	300
% Agreement	95%	>99%	98%

When compared to GC/MS at the cut-off of 300 ng/mL, the following results were tabulated:

Method	GC/MS		Total Results
	Positive	Negative	
COC One Step Test Strip	Positive	17	136
	Negative	159	164
Total Results	124	176	300
% Agreement	96%	90%	93%

Analytical Sensitivity

A drug-free urine pool was spiked with Benzoylgonine at the following concentrations: 0 ng/mL, 150 ng/mL, 225 ng/mL, 300 ng/mL, 375 ng/mL and 450 ng/mL. The result demonstrates > 99% accuracy at 50% above and 50% below the cut-off concentration. The data are summarized below:

Benzoylgonine Concentration (ng/mL)	Percent of Cut-off	n	Visual Result	
			Negative	Positive
0	0%	30	30	0
150	-50%	30	30	0
225	-25%	30	30	0
300	Cut-off	30	4	26
375	+25%	30	0	30
450	+50%	30	0	30

Analytical Specificity

The following table lists compounds that are positively detected in urine by the COC One Step Cocaine Test Strip (Urine) at 5 minutes.

Compound	Concentration (ng/mL)
Benzoylgonine	300
Cocaine HCl	780
Cocaine	12,500
Egonine HCl	32,000

Precision

A study was conducted at three physicians' offices by untrained operators using three different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens containing, according to GC/MS, no Benzoylgonine, 25% Benzoylgonine above and below the cut-off and 50% Benzoylgonine above and below the 300 ng/mL cut-off was provided to each site. The following results were tabulated:

Benzoylgonine Concentration (ng/mL)	n per Site	Site A		Site B		Site C	
		Pos.	Neg.	Pos.	Neg.	Pos.	Neg.
0	15	0	14*	0	15	0	15
150	15	1	14	0	15	1	14
225	15	11	4	10	5	7	8
375	15	15	0	15	0	15	0
450	15	15	0	15	0	14	1
Non Valid	15	16/16		15/15		15/15	

*Note: Non-valid results were obtained in this treatment. Non-valid tests were provided as part of this study to ensure that readers would accurately identify non-valid test results.

Effect of Urinary Specific Gravity

Fifteen urine specimens of normal, high, and low specific gravity ranges were spiked with 150 ng/mL and 450 ng/mL of Benzoylgonine. The COC One Step Cocaine Test Strip (Urine) was tested in duplicate using the fifteen neat and spiked urine specimens. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results.

Effect of Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with Benzoylgonine to 150 ng/mL and 450 ng/mL. The spiked, pH-adjusted urine was tested with the COC One Step Cocaine Test Strip (Urine) in duplicate. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-negative urine or Benzoylgonine positive urine. The following compounds show no interference when tested with the COC One Step Cocaine Test Strip (Urine) at a concentration of 100 µg/mL.

Non Cross-Reacting Compounds

Acetaminophen	Diazepam	Metadone	Prednisone
Acetophenetidin	Diclofenac	Methoxyphenamine	Procaine
N-Acetylprocainamide	Diffunilal	(±)-3,4-Methylenedioxy-amphetamine	Promazine
Acetylsalicylic acid	Digoxin	(±)-3,4-Methylenedioxy-methamphetamine	D,L-Propranolol
Aminopyrine	Diphenhydramine	Morphine-3-β-D-glucuronide	D-Propraxophene
Amitypyline	Doxylamine	Quinine	Ranitidine
Amobarbital	Egonine methylester	Salicylic acid	Secobarbital
Amoxicillin	(-)-Ephedrine	Naltrexone	Serotonin
Ampicillin	Erythromycin	Naproxen	Sulfamethazine
L-Ascorbic acid	β-Estradiol	Niacinamide	Sulindac
D,L-Amphetamine sulfate	Estrone-3-sulfate	Nifedipine	Temazepam
Apoporphine	Ethyl-p-aminobenzoate	Norcodine	Norethindrone
Aspartame	Fenpropfen	Hydralazine	Hydrochlorothiazide
Atropine	Furosemide	Bilirubin	Hydrocodone
Benzic acid	Genisteic acid	(±)-Brompheniramine	Hydrocodone
Benzoic acid	Hemoglobin	Caffeine	Hydrocortisone
Benzphetamine	Hydralazine	Canabidol	O-Hydroxyhippuric acid
Bupropion	Hydrochlorothiazide	Cannabiol	p-Hydroxy-methamphetamine
(±)-Brompheniramine	Hydrocodone	Chloralhydrate	3-Hydroxytyramine
Calcitriol	Hydrocortisone	Chloramphenicol	Oxycodone
Canabidol	O-Hydroxyhippuric acid	Chloridiazepoxide	Ibuprofen
Cannabiol	p-Hydroxy-methamphetamine	Chlorothiazide	Imipramine
Chloralhydrate	3-Hydroxytyramine	(±)-Chlorpheniramine	Iproniazid
Chloramphenicol	Oxycodone	Chlorpromazine	(±)-Isoproterenol
Chloridiazepoxide	Oxymetazoline	Chlorquine	Isoxsuprine
Imipramine	Papaverine	Cholesterol	Ketamine
(±)-Chlorpheniramine	Penicillin-G	Clomipramine	Ketoprofen
(±)-Isoproterenol	Pentobarbital	Clonidine	Labelolol
Isoxsuprine	Perphenazine	Cocaine	Levorphanol
Ketamine	Phencyclidine	Cortisone	Loperamide
Ketoprofen	Phentermine	(-) Cotinine	L-Phenylephrine
Labelolol	Phenobarbital	Creatinine	β-Phenylethylamine
Levorphanol	Phentemine	Deoxycorticosterone	Phenylpropanolamine
Loperamide	Phenylephrine	Dextromethorphan	Prednisolone
L-Phenylephrine	Uric acid		
β-Phenylethylamine	Verapamil		
Phenylpropanolamine	Zomepirac		
Prednisolone			

BIBLIOGRAPHY

- Stewart DL, T Inoba, M Ducassen, W Kalow. Clin. Pharmacol. Ther. 1979; 25:264
- Ambr J. J. Anal. Toxicol. 1985; 9:241
- Baselt RC. Disposition of Toxic Drugs and Chemicals in Man, 2nd Ed. Biomedical Publ., Davis, CA. 1982: 488
- Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986

Index of Symbols

	Storage Temperature		Manufacturer		Do not reuse
	Lot Code		Authorized Representative		For in vitro diagnostic use
	Expiration		Caution, see instructions		Catalog No.

BIOMERICA, Inc.
17571 Von Karman Ave.
Irvine, CA 92614 USA



acc.to IVDD 98/79/EC
MDSS GmbH
Schiffgraben 41
30175 Hannover, Germany